Fisetin: The Natural Senolytic Compound for Healthy Aging

Fisetin is a flavonoid polyphenol found naturally in strawberries, apples, persimmons, and other fruits and vegetables. While it has long been recognized for modest antioxidant properties, its emergence as one of the most potent natural senolytics identified to date has made it a focal point of aging research — and a growing staple in the longevity medicine toolkit.

What Are Senolytics?

Cellular senescence occurs when cells become damaged or reach the end of their replicative lifespan and stop dividing — but instead of dying, they persist in a dysfunctional state. These "zombie cells" are metabolically active and secrete a chronic inflammatory cocktail of cytokines, proteases, and growth factors called the Senescence-Associated Secretory Phenotype (SASP).

SASP drives:

• Chronic systemic inflammation ("inflammaging")
• Tissue dysfunction and organ aging
• Neighboring cell senescence (bystander effect)
• Increased risk of age-related diseases including cancer, cardiovascular disease, neurodegeneration, and diabetes

Senolytics are compounds that selectively eliminate senescent cells, reducing SASP burden and allowing the body's regenerative processes to function more effectively. The first FDA-designated senolytic trial used the combination of dasatinib (a cancer drug) and quercetin — but fisetin has since been identified as potentially more potent and better tolerated for human use.

Why Fisetin Stands Out Among Natural Senolytics

A 2018 landmark study published in EBioMedicine by the Mayo Clinic's aging research group systematically screened ten natural compounds for senolytic potency in human adipose tissue. Fisetin emerged as the most potent natural senolytic tested, outperforming quercetin, curcumin, resveratrol, kaempferol, and seven others in its ability to selectively clear senescent cells while leaving healthy cells unharmed.

In the same study, oral fisetin treatment in aged mice:

• Significantly reduced senescent cell burden in multiple tissues
• Reduced inflammatory SASP markers including IL-6, TNF-alpha, and MMP-9
• Restored tissue homeostasis in aging brain, liver, kidney, and adipose tissue
• Extended median and maximum lifespan by approximately 10% even when started in late life

Mechanisms of Action

Fisetin's senolytic effects appear to operate through several complementary pathways:

BCL-2/BCL-XL Inhibition

Senescent cells resist apoptosis (programmed cell death) by upregulating survival proteins including BCL-2 and BCL-XL. Fisetin inhibits these anti-apoptotic proteins, selectively tipping senescent cells toward cell death while normal cells — which are not dependent on these same survival signals — are spared.

PI3K/AKT/mTOR Pathway Modulation

Fisetin inhibits the PI3K/AKT/mTOR signaling cascade that drives SASP expression in senescent cells, simultaneously reducing inflammatory cytokine secretion even in cells it doesn't fully eliminate.

Nrf2 Activation

Fisetin activates the Nrf2 antioxidant response pathway, enhancing cellular defense against oxidative stress — one of the primary drivers of DNA damage and senescence induction. This gives fisetin a dual role: both preventing new senescent cells from forming and clearing existing ones.

Fisetin and Brain Health

Beyond senolysis, fisetin has been extensively studied for neuroprotective effects:

• Increases BDNF (brain-derived neurotrophic factor), supporting synaptic plasticity and memory consolidation
• Reduces neuroinflammation via NF-κB inhibition
• Demonstrates protective effects against amyloid-beta toxicity in Alzheimer's disease models
• Improves spatial memory and object recognition in aging rodent studies

A clinical trial (NCT02741791) at the University of Minnesota is investigating fisetin's effects on older adults with mild cognitive impairment, with preliminary results suggesting cognitive and functional benefits.

Dosing and Protocols

Human clinical data on fisetin dosing is still emerging, but current research-informed protocols typically involve:

• Senolytic pulse dosing: High-dose fisetin (20 mg/kg body weight, or approximately 1,000–1,500 mg for most adults) taken for 2 consecutive days, repeated every 1–3 months. This intermittent approach mirrors the "burst" senolytic approach used in clinical trials.
• Daily low-dose maintenance: Some longevity physicians recommend 100–200 mg daily for ongoing anti-inflammatory and neuroprotective benefits, separate from senolytic pulse protocols.

Fisetin has poor oral bioavailability in standard formulations. Taking it with a high-fat meal or in a lipid-based carrier (oil or fat-containing food) significantly improves absorption. Emerging nano-formulations and liposomal fisetin products are showing substantially higher bioavailability in preliminary studies.

Safety Profile

Fisetin has a favorable safety profile in available research. It is generally well tolerated, with no significant adverse effects reported in preclinical studies at relevant doses. Human trials to date have found no clinically meaningful toxicity. As with all supplements, individuals on anticoagulants or chemotherapy should consult their physician before use, as fisetin may interact with these agents.

Frequently Asked Questions

How does fisetin compare to quercetin as a senolytic?

In the landmark Mayo Clinic screening study, fisetin was more potent than quercetin at equivalent concentrations. However, quercetin combined with dasatinib (the D+Q protocol) has more clinical trial data in humans. Many longevity practitioners use fisetin as a safer, natural alternative to D+Q for individuals who prefer to avoid pharmaceutical agents.

How much fisetin is found in food?

Strawberries are the richest dietary source at approximately 160 mcg/g, meaning you'd need to eat about 37 pounds of strawberries to obtain a single 3 mg/kg dose used in research. Dietary intake cannot replicate therapeutic senolytic doses — supplementation is required for research-grade effects.

Should I combine fisetin with other senolytics?

Some longevity protocols combine fisetin with quercetin and/or dasatinib for potentially synergistic senolytic effects. However, combining agents increases complexity and interaction risks. A conservative approach is to start with fisetin alone and consult a longevity medicine specialist before layering additional senolytics.